This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my last update for April if you missed it.
ARCTF LUNMF NSRPF NEM YRI KGI.DB CG LUNCF MAX TMMFF NXXGD NSU CAGDF RSG AMI NXXGF AUY EDVVF RMGGF MDRPF IAG KL ABX EDV SAND SSL ABX SDDXF KGI NXS KGI.DB.A EDVMF NVO SNXZF ORG LUN TMR RMGGY EVR CANWF
VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX) (OTCQX:MDRPF) (“Midas Gold” or the “Company”) today announced that it has increased the size of its board of directors from seven to eight and appointed Mark Hill, Chief Investment Officer with Barrick Gold Corporation (NYSE:ABX) (TSX:ABX) (“Barrick”) to fill the additional position. The increase in board size and the appointment of a Barrick nominee to the board of directors is in accordance with the terms of the investor rights agreement entered into with Barrick in conjunction with the strategic investment by Barrick in Midas Gold that was completed on May 16, 2018.
ABX BLT BHPBF AU MAX AULGF BHP BBL MDRPF AGG BHP BHPLF ABX
Barrick Gold Corporation (ABX - Free Report) has purchased 46,551,731 common shares of Midas Gold Corp. for gross proceeds of roughly $38.1 million in a non-brokered private placement. As a result, Barrick Gold now owns 19.9% of issued and outstanding shares in Midas Gold. Barrick Gold’s latest move supports the continued efforts of Midas Gold to complete a feasibility study and permitting of the Stibnite Gold Project in Idaho.
HUN ABX WLK MDRPF MAX CC ABX
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX) (OTCQX:MDRPF) (“Midas Gold” or the “Company”) today announced that Barrick Gold Corporation (NYSE:ABX) (TSX:ABX) (“Barrick”) has purchased 46,551,731 common shares of Midas Gold in a non-brokered private placement (the “Placement”) at a price of C$1.06 per share for gross proceeds of US$38,065,907. As a result of the Placement, Barrick owns 19.
ABX MDRPF DTK MAX ABX
The West Texas Intermediate crude recently reached its highest point since November 2014, hitting $71.36 a barrel after President Trump’s announcement that the U.S. would pull out of the Iran nuclear deal.
RDS.B RDS.A XOM CVX RYDBF MDRPF MAX RDSB RDSA RYDAF
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 6 cents per share in the first quarter of 2018, in line with the Zacks Consensus Estimate and with the year-ago quarter.
ENTA CPRX LGNZZ LGND LGNYZ MDRPF CATB LGNXZ MAX LGNDZ
Gerdau S.A. reported impressive results for first-quarter 2018. The Brazilian steel maker’s adjusted net income totaled R$451.1 million ($138.8 million) in the reported quarter versus net loss of R$34.146 ($10.9 million) incurred in the year-ago quarter. The bottom line benefited from higher revenue generation, rise in adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) and fall in financial expenses.
MT STLD MDRPF MAX MT NUE
Inovio Pharmaceuticals, Inc. (INO - Free Report) reported a loss of 36 cents in the first quarter of 2018, wider than both the Zacks Consensus Estimate of a loss of 27 cents and the year-ago loss of 31 cents.
AZN INO AZN MDRPF MAX
Barrick Gold Corporation (ABX - Free Report) has inked a subscription agreement to acquire 46,551,731 common shares of Midas Gold Corp., for gross proceeds of roughly $38.1 million in a non-brokered private placement. The company expects the deal to close on or about May 15, following which, it will own roughly 19.9% of the outstanding common shares of Midas Gold, on a non-diluted basis. According to Barrick Gold, Midas Gold’s Stibnite Gold project in Idaho has low geopolitical risk.
HUN ABX STLD MDRPF MAX CC ABX
If you think Iran is the only current hot spot, all you need to do is look around the world, and there are numerous places where things could flare up. While the situation on the Korean Peninsula looks better than any time in recent history, the North Koreans have been known to bait and switch, and we still face the potential for trouble in Syria, Afghanistan and across the Middle East.
ABX MDRPF MAX GG ABX
VANCOUVER, British Columbia, May 10, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX) (OTCQX:MDRPF) ("Midas Gold" or the "Company") today announced the results of its annual general meeting (the “AGM”), which was held in Vancouver on May 9, 2018. Following the meeting, Stephen Quin, President and CEO, provided those present with an overview of the Company’s progress over the past year and its plans going forward.
TORONTO, May 09, 2018 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:ABX) (TSX:ABX) (“Barrick”) announced today that it has entered into a subscription agreement to acquire 46,551,731 common shares of Midas Gold Corp. (“Midas Gold”) in a non-brokered private placement at a price of C$1.06 per share for gross proceeds of US$38,065,907.
ABX MDRPF MAX ABX
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET